Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer

• Published in: Oncotarget 2017-02, Vol.8 (9), p.15610-15620
• Main Authors: Blok, Erik J, van den Bulk, Jitske, Dekker-Ensink, N Geeske, Derr, Remco, Kanters, Corné, Bastiaannet, Esther, Kroep, Judith R, van de Velde, Cornelis J H, Kuppen, Peter J K
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - therapy; CD8-Positive T-Lymphocytes - metabolism; Cohort Studies; fas Receptor - biosynthesis; fas Receptor - genetics; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating - metabolism; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Outcome Assessment (Health Care) - methods; Outcome Assessment (Health Care) - statistics & numerical data; Prognosis; Proportional Hazards Models; Receptors, Estrogen - genetics; Receptors, Estrogen - metabolism; Research Paper; Reverse Transcriptase Polymerase Chain Reaction; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - therapy
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.14779

Multiple studies showed the prognostic capacities of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC), but not in other subtypes. We evaluated tumor expression of FAS, a key receptor in T-cell mediated apoptosis, as possible explanation for this differential prognostic value of TILs. Furthermore, we evaluated the prognostic relevance of FAS, both as an independent biomarker and in relation to CD8-positive T-cell presence. The study cohort consisted of 667 breast cancer patients treated in the LUMC between 1997 and 2009. FAS expression was determined using immunohistochemistry and the percentage of FAS-positive tumor cells was quantified. Furthermore, the number of CD8-positive infiltrating cells was determined, and its prognostic relevance was associated to FAS-expression using stratified survival analysis. In TNBC, FAS was averagely expressed in 49% of tumor cells, whereas ER-positive subtypes showed an average Fas expression of 16-20%. In the entire cohort, FAS was identified as significant prognostic marker for recurrence (adjusted HR 0.53, 95% CI 0.36-0.77) and borderline significant marker for overall survival (adjusted HR 0.72, 95% CI 0.52-1.01). Upon stratification for FAS-expression, CD8+ TILs were only prognostic at high levels (above median) of FAS expression in ER-negative disease. In summary, FAS was identified as an independent prognostic marker for recurrence free survival in breast cancer, with large variation in expression by receptor subtypes. Interestingly, the prognostic effect of CD8+ TILs in ER-negative disease was only valid for tumors with a high FAS expression.